Filing Details

Accession Number:
0001714899-23-000125
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-16 18:20:02
Reporting Period:
2023-08-14
Accepted Time:
2023-08-16 18:20:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724605 Carole Ho C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-14 2,768 $23.79 182,809 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 25,000 Indirect See footnote
Common Stock 114,124 Direct
Footnotes
  1. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 30, 2023.
  2. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
  3. The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
  4. Includes 113,714 RSUs.